Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
Kiran NaqviElias J JabbourJeffrey SkinnerMusa YilmazAlessandra FerrajoliPrithviraj BosePhilip ThompsonYesid AlvaradoNitin JainKoichi TakahashiJan BurgerZeev EstrovGautam BorthakurNaveen PemmarajuShilpa PaulJorge CortesHagop M KantarjianPublished in: Cancer (2018)
Dasatinib 50 mg daily is active and well tolerated in patients with newly diagnosed CML-CP. It should be further explored as a new potential standard-of-care option for chronic myeloid leukemia. Cancer 2018;124:2740-2747. © 2018 American Cancer Society.